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Abstract
Asthmatic diseases have been reported since the ancient world. Hay
fever for instance, was described for the first time in the late 18
th cen-
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tury, and the term “allergy” was introduced about 100 years ago. Today
the incidence of allergies is rising; almost one third of the Western
population suffers from its side effects. Allergies are some of the most 1 Zentrum für Rhinologie und
Allergologie, Wiesbaden,
Germany
chronic medical complaints, which results in high health expenditures.
Therefore, they have a large health and political relevance.
Causedbygeneticandenvironmentalfactors,thegroupofIgEmediated
allergies is large. It consists of e.g. atopic dermatitis, allergic asthma
or allergic rhinitis. This paper aims to emphasize the ways of early
diagnosis of allergic rhinitis (AR) as AR represents the most important
representative of allergic diseases in ENT.
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1 Introduction
Bronchial asthma has been reported since the ancient
world, in contrary to hay fever that, was described for the
first time in the late 18
th century.
Interestingly, mainly aristocrats/wealthy people were
those affected in former times.
Today, allergies are widespread; almost one third of the
Western population suffers from its clinical implications.
Allergiesbelongtothemostfrequentchronicailmentthat
causeshighhealthexpendituresduetohightherapycosts
and inability to work or go to school. In this way they have
a large health and political relevance.
The word “Allergy”originates from the Greekword “allos”
(“change of the original status”).
Thedefinitionisbasedontheconceptthattheexposition
to an extraneous material would induce a change of re-
activity in persons towards their ambience. Subsequent
contactswiththesubstancewouldeitherincreasereactiv-
ity (hypersensitivity) or decrease reactivity (hyposensitiv-
ity/immunologic tolerance). Gell and Coombs suggested
classifyingallergicreactionsinfourdifferentimmunologic
mediated categories (Table 1). Type I was defined as the
IgE mediated reaction that appeared immediately.
The term atopic disease is commonly used for illnesses
thatareaccompaniedbythedetectionofallergenspecific
IgE-antibodies such as atopic dermatitis, allergic rhinitis
or bronchial asthma. In spite of this common property,
those afore-mentioned atopic diseases show display
geneticandenvironmentaldeterminantsandriskfactors.
This review paper is meant to emphasize that the early
diagnosis of allergic rhinitis (AR) is the most important
factor in avoiding the development of other allergic dis-
eases namely of bronchial asthma and to achieve suc-
cessful treatment.
Early diagnosis of allergic diseases is even more import-
ant considering the fact that early treatment of allergic
sensitization can prevent clinical manifestation, exacer-
bation or expansion of allergic diseases to other organ
systems (secondary prevention).
Primary prevention on the one hand means eliminating
or at least diminishing factors causing the onset of a
disease.This includesalterationsofcausalorpredispos-
ing environmental or workplace factors. On the other
hand, it means increasing the individual tolerance.
Primary prevention is particularly probable for at-risk
groups (genetic prestressed persons). In a certain way
this might apply to the total population as well as includ-
ing allergy specific health promotion.
Targetsofsecondarypreventionareindividualsthatshow
earlysymptoms(e.g.bronchialornasalhyperresponsive-
nessordetectedsensitization)andsensitizedasymptom-
atic persons. Secondary prevention should obviate
manifestation or symptom alteration.
This can be achieved by avoiding clinically relevant aller-
gensandtoxicirritantsubstances,consultativeactivities,
prophylacticactivitiesorallergenspecificimmunotherapy
(hyposensitization).
Avoiding new onsets of other atopic or allergic diseases
can be added to secondary prevention as well.
2 Allergic rhinitis
Allergic rhinitis (AR) manifests itself in 20% of a person's
lifetime,andthereforeisoneofthemostfrequentallergic
diseases (Review in [1]). Its clinical manifestation often
begins in early childhood, and leads to annoying symp-
toms that can last one's whole life. It can influence the
social life, academic capacity and labor productivity of
theaffectedpatients.Typically,thereisahighcomorbidity
described such as conjunctivitis, asthma, food allergy,
atopic dermatitis, sinusitis among others. Patients suf-
fering from allergic rhinitis seem to develop bronchial
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Table 2: Classification of allergic rhinitis (according to [1])
asthma3.2timesmoreoftenthanhealthyhumanbeings
[2].Thisisexpressedintheinitiative"AllergicRhinitisand
its Impact on Asthma (ARIA)" among others that was de-
veloped and published in collaboration with the World
health organization (WHO) [1]. The comorbidities listed
above motivate to diagnose and treat allergic rhinitis as
early as possible (secondary prevention). It was proven
that early diagnosis of allergic diseases can improve effi-
ciency of specific immunotherapy, avoid comorbidities
(e.g.bronchialasthmawithpatientssufferingfromallergic
rhinitis) and can decrease the enlargement of the sensi-
tization-spectrum [1], [3]. This considerably affects the
health expenditures evoked by this disease pattern.
The social-economic consequences caused by allergic
rhinitis and its comorbidities are tremendous. They arise
from direct, indirect and intangible costs of the health
system and the overall economy [3]. In 2000, the ex-
penses of AR amounted to about 240 million Euros, and
the expenses of the total allergic respiratory disorders
(consequently including all comorbidities of AR) were es-
timated to be 5.1 billion Euros [4].
Therefore it must to be noted that according to the white
paper“AllergyinGermany”,only10%ofthepatientswith
AR are treated according to the actual guidelines, and
only one third of the patients are treated at all [3].
Allergic rhinitis is clinically defined as a symptomatic
disease of the nose induced by IgE mediated inflamma-
tion of the nasal mucosa after exposure to allergens.
Clinically, AR can be subdivided in seasonal, perennial
or work-related types, but this classification can not be
usedconsistently.Seasonalallergensarepresentalmost
allyear.Perennialallergensshowseasonalupswingsand
downturns in their level of exposure throughout the year.
Nevertheless, allergen-exposure and symptoms do not
correlate definitely, and therefore therapeutic con-
sequences cannot be drawn directly.
A work group of the WHO suggested a new classification
emphasizingthedurationofsymptoms(Table2,[1]).The
severity of symptoms should be defined by means of its
effects on the quality of life of the patients.
2.1 Basic pathophysiological principles
of allergic rhinitis
Allergic rhinitis is characterized by cellular inflammatory
reactions that can be divided experimentally and partly
clinically in an early phase reaction and a late phase re-
action.Thefollowingprocessesareincludedinthisinflam-
matory reaction [1]:
• Release of mediators such as histamines (essential
marker of the early phase reaction), arachidonic acid
meta-bolites (cyteinyl leukotrienes), and kinines
• Release of pro-inflammatory and TH2- associated
cytokines and chemokines
• Expressionofadhesionmolecules,selectivecellrecruit-
ing and transendothelial migration of cells
• Activation and differentiation of eosinophiles, T-
lymphocytes, B-lymphocytes, mast cells, basophiles,
endothelial- and epithelial cells, fibroblasts
• Lifetime extension of inflammatory cells
• Regulation of local and systemic IgE-response, in-
creased expression of IgE-receptors
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To some extent, the release of mediators of AR, as well
as symptoms of AR can be imitated by provocation with
e.g. pollen allergens. This test differs noticeably from the
natural allergen exposure. An early phase reaction can
be reproduced in allergic patients when exposed to low
doses of allergens. Late phase reactions require higher
(oftennotphysiological)amountsofallergens.Theinten-
sity of the reaction of the nasal mucosa to an allergen-
exposure depends on the degree of mucosal inflamma-
tion; the intensity of the reaction varies throughout the
year [5]. “Priming” describes an increased reaction
caused by repeated exposure [6].
“Minimalpersistentinflammation”isanewandimportant
concept: after an allergen-exposure or after a low expos-
ure, inflammatory parameters keep their high level even
thoughthepatientsarenotsufferingfromanysymptoms
[7]. The persistent allergic rhinitis is characterized by
interactingallergictriggerswiththissustainedinflammat-
ory reaction. The pathology is then based on a complex
interaction.
Animportantattributeofallergicrhinitisisnasalhyperre-
activity. Hyperreactivity is an intensified response to un-
specific stimuli (smoke, dust, odorous substances, alter-
ationsintemperatureandefforts),andleadstosneezing,
nasal obstruction or nasal secretion.
Comorbidities of allergies and their early diagnosis are
considerably influenced by the immunological mechan-
isms of the pathophysiological processes; which will be
explained in detail in the following segment.
Antigen presenting cells (APC) and induction of specific
sensitization
Allergens first penetrate the epithelial barrier of respira-
tory tract, gastrointestinal tract or dermis of the body.
There,specializedandhighlycapableantigenpresenting
cells (dendrite cells, Langerhans cells) absorb allergens
as total proteins and process them.
In this way, the allergen decomposes into peptides and
is bound to MHC-complexes. Thus it is presented to T-
cellsinthiskindoflinkage(primarilylocatedinthelocally
drained lymph nodes, where APC migrate to) [8].
Subsequently, specific native T-cells with suitable recep-
torsareactivated,theyproliferateandreturnconsistently
as“Memory-T-cells”totheaccordanttissue(Homing)[9].
There they can react again after allergen exposure. Be-
sidesthedescribedspecificinteractionofAPCandT-cells,
costimulatingsignalsarenecessarytocompletelyactivate
T-cells.Theyconsistofinteractionswithmembrane-bound
molecules such as B7-group on APC or CD 28 on T-cells
andinteractionswith solublemediators suchas interleu-
kin 1. Lack of these signals does not lead to sensitiza-
tions, rather, it leads to anergy of T-cells (status of no
excitability). This is then followed by the death of the T-
cellsandimmunologicaltolerance[10].Thedeactivation
ofimmuneresponsesmattersagreatdealfortheregula-
tionoftheimmunesystem,especiallytoavoidmisguided,
overshooting or never-ending reactions.
2.2 TH1/TH2-Dichotomy
Besides the old classification of T-cells in CD4
+, T-helper
cells and CD8
+ cytotoxic-suppressor cells, a new classifi-
cation of T-helper cells has been established according
to their cytokine production pattern. Native (not deter-
mined) CD4
+ T-cells are called TH0-cells. They can differ-
entiate to TH1-cells which produce interferon (IFN)-
gamma,tumournecrosisfactor(TNF)-alphaorinterleukin
(IL)-2 among others or to TH2-cells which IL-4, 5, 6 and
13 [11]. Both cell types produce their own growth factors
(IL-2 and accordingly IL-4), and they inhibit the respective
processing of other TH-type (IFN-gamma of TH1 inhibits
TH2; IL-10 of TH2 inhibits TH1). Costimulating signals
(maybesomedifferenttypesofAPCaswell),butprimarily
certaincytokinescanfavouronecourseofeitherTH-type.
So IL-4 supports the TH2-development and IL-12 favours
the TH1-development [12], [13]. In turn the cytokine-
ambience of mucous membranes and skin is formed
primarily by the cells of epithelial cell organisations.
2.2.1 B-cells and IgE-production
High IgE-level characterize atopic diseases [14]. Mainly
IL-4 (and IL-13) activates the class switch of immuno-
globulins of B-cells according to specific gene products
which code for various IgE- types. Furthermore, IL-4 sup-
ports the production of IgE by plasma cells [12]. The in-
duction of class switch of immunoglobulins is also influ-
enced by the interaction of the membrane-bound mol-
ecules CD40L of activated T-cells and CD40 of B-cells
[15]. Furthermore, IL-6 can activate the immunoglobulin
production generally. Moreover, several other signals
exist that can manipulate IgE production. One such rep-
resentative is IFN-gamma, the most important inhibitor
ofIgEproduction[16].IFN-gammaissynthesizedbyTH1-
cells and CD8
+ T-cells, and therefore the cells tend to in-
hibit IgE production (in contrast, there are CD8
+ T-cells
thatproduceTH2-typecytokinestoo).ThusTH2-cellscan
initialize positive signals for IgE production (CD40L and
IL-4), which canindeedcanbe foundwith atopic patients
[17], [18]. The total process described above is called
Allergen Specific Induction of TH2-cells, which helps B-
cells produce allergen specific IgE, thus completing the
induction of a type-1-sensitization.
Allergens triggering IgE mediated type-1-allergies are
usually complex molecules (proteins or glycoprotein’s)
composed of a high number of amino acids in a defined
sequence (primary structure) which is arranged in a spe-
cific way (secondary structure). In turn, bigger subunits
of such a molecule fold themselves characteristically
(tertiary structure). The parts of allergens recognized
specifically by T-cells (variable region of the T-cell-recep-
tor) are denominated T-cell epitopes (Figure 1); normally
they are peptides (primary structure). Parts of allergens
that are identified by B-cells (variable regions of the im-
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munoglobulins)arecalledB-cellepitopes(mainlydepend-
ent on conformation, tertiary structure).
2.2.2 Mast cells and “immediate phase
reaction”
After occurred sensitization with allergen specific IgE-
production, new allergen contact induces de-granulation
of mast cells or basophiles if multiple FcepsilonRI-bound
IgE-molecules are cross-linked. Anti-IgE- or Anti-Fcepsi-
lonRI-antibodiesandnon-specificfactorslikecomplement
factors (C3a, C5a), thrombin as well as insect venoms,
Ca-ionophore, pharmaceuticals and toxines can evoke
mast cell- or basophile-degranulation, too [19]. Further-
more, “releasability” of mastcells and basophiles is
modulated by cytokines such as IL-3 and neuro-transmit-
ters like substance P (SP), vasoactive intestinal poly-
peptide (VIP) and somatostatine [20].
Degranulationofmastcellsorbasophilsleadstorelease
of several preformed mediators or newly synthesized
mediatorssuchashistamine,prostaglandins,leukotrines,
kinins, plattlet- activating factor (PAF), cytokines (IL-3, 4
and5),proteases(tryptase,chymase,carboxypeptidase)
and proteoglycanes [19]. Firstly, this causes the “imme-
diatereaction”withoedema(wheal)anderythemaatthe
location of allergen exposure or can trigger a systemic
anaphylactic reaction within a few minutes. Secondly,
mast cell mediators or mediators of other cells can pro-
voke a “late phase reaction”.
2.2.3 Eosinophiles, “late phase reaction” and
chronic allergic inflammation
Usually, a “late phase reaction” (differentiate from the
type of allergy that appears delayed) occurs a few hours
afterallergenexposure.Typically,basophilesandeosino-
philes are migrating into the tissue attracted by chemo-
tactic factors like PAF, C5a, prostaglandins and leuko-
trienesandcytokines[21],[22].Thosecellsproducepro-
inflammatorymediatorsandenzymeswhichcandamage
tissuelike majorbasic protein (MBP), eosinophile-peroxi-
dase (EPO), collagenase, phosphatase, arylsulfatase,
eosinophile cationic Protein (ECP), eosinophile protein X
(EPX), eosinophilie-neurotoxin (EDN), leukotrienes,
prostaglandins, PAF and oxygen radicals (Figure 2) [19].
The determination of the ECP-level is a good activity-
marker of atopic diseases.
Atthemoment,itismainlynotsolvedwhichfactorscould
help to switch those inflammatory processes off. T-cells
seem to be important in regulation of the allergic inflam-
mation. T-cells as well as other cells like mast cells show
the abilityto produceimportantregulative mediators like
IL-4. IL-4 induces e.g. adhesion molecules like VCAM-1
(vascular cellular adhesion molecule) at vessels of the
affectedtissue.Inthiswayitstimulatesdirectlymigration
ofbasophilesandeosinophileshavingsuitablereceptors
to VCAM-1, VLA-4 (very late antigen) [9]. Mediators like
TNF-alpha, IL-1 and IFN-gamma play decisive roles in
regulatingotheradhesionmoleculeslikeseveralselectins
or integrins [23].
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2.3Clinicalsymptomsofallergicrhinitis
(AR), comorbidities
The clinical symptoms of allergic rhinitis are the cardinal
symptoms: sneezing, nose itching, clear nasal secretion
and nasal obstruction. The rhinitis caused by pollen is
characterized by sneezing, nasal secretion and concomi-
tant conjunctivitis. In contrast, rhinitis caused by mite al-
lergensespeciallygeneratesnasalobstruction.According
to the new definition, all symptoms are represented
equivalently in case of the persistent rhinitis.
It was estimated [24] that about 20% of nasal allergies
are caused by seasonal, 40% by perennial allergens and
40%aremixedmanifestationtypes.Firstepidemiological
researches according to the new definition show that
about one third of all AR patients suffer from persistent
AR and two thirds suffers from intermittent AR.
Comorbiditiesofallergicrhinitisarevariousandrelevant.
Disturbances of life quality and productivity induced by
AR vary from sleep disorders to daytime fatigue [25], on
to the reduction of learning aptitude of children [26]. Ac-
cording to a trial that included 69 children with seasonal
allergic rhinitis [27], 80% suffered from pharyngitis, 70%
from conjunctivitis, 40% from asthma and 37% from
atopic eczema. In several trials especially asthma was
discoveredtobeanimportantcomorbidityofAR:children
withafrequencyof32%[28]andadultswithafrequency
of 16% [29]. The opposite way around over 80% of asth-
matic patients suffer from AR too. Sinusitis exhibits a
coincidence of 25% [30]. The latter represents another
important disease contributingto the patients’ morbidity
and should be considered differential diagnosis. This
does not fit for nasal polyps that are not associated with
allergic rhinitis [31], [32]. Serous otitis media seems to
be disproportionately associated with an allergy [33]. In
the case of children, habitual snoring and obstructive
sleep apnoea are related to allergies [34].
2.4 Increasing prevalence of allergies
Clinical trials that evaluate the prevalence of allergic
diseases demonstrated decisive differences between
EasternandWesternEurope.Thereby,auniquesituation
existed in Germany. Almost as in a natural experiment,
populationgroupshavingsimilargeneticdispositionshad
been exposed to very different environmental influences
in the Eastern versus in the Western part of the country
over several decades. Those general living conditions
haveledtoobviousdifferencesinmanifestationofatopic
diseases in children as well as in adults. In Munich for
instance, the prevalence of hay fever (8.6% versus 2.7%,
p<0.0001),bronchialasthma(9.3%versus7.2%,p<0.05)
and bronchial hyper-reactivity (8.3% versus 5.5%,
p<0.001) has been reported to be significantly higher
than in Leipzig and Halle in school children of the ages
9–11 years [35].
The frequency of atopic sensitizationsmeasuredby skin-
prick-test showed less positive results in children from
EasternGermanythaninchildrenfromWesternGermany
too (18.2% versus 36.7%, p<0.001) [35]. In a similar
comparative trial analysing children of the ages 10–12
years, it was noticed that the prevalence of atopic sensi-
tizations in Estonia and Poland was less than in Sweden
(13.6% versus 19.9% versus 30.3%, p<0.001).
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childhood
Withincreasingagethespectrumofatopicsensitizations
changes in children. Primarily, during infancy IgE-anti-
bodies are produced against food allergens especially
bovine milk and egg white of chicken which can lead to
different clinical symptom patterns.
They can cause dermatological syndromes (atopic
dermatitis, urticaria), gastro-intestinal discomforts and
rarely respiratory troubles. Sensitizations to mite, cat
epitheliaorotherindoorallergensdeveloplateronduring
toddlerhoodandschoolage.Thepeakofpollensensitiza-
tionaswellastheincidenceofhayfevershowsuparound
adolescence.
2.6 Risk factor for the development of
allergies
In order to apply early diagnosis of allergic diseases well-
directed, possible risk populations have to be defined
that account for higher risks to develop allergies. In the
following part risk factors for development of allergies
are listed according to the actual existing data.
2.6.1 Intrinsic factors
Familiar disposition
It is well documented that a positive family history of
atopic diseases represents a risk factor for developing
bronchial asthma, hay fever and atopic dermatitis. The
more family members are affected the higher the risk
that the child will develop atopic diseases [36].
Also twin trials showed that the concordance of atopic
diseases is higher with monozygotic twins than with
dizygotic twins [36]. Therefore, few doubts exist that eti-
ologyofatopicdiseasesismainlycomprisedofhereditary
components. Nevertheless allergic diseases display
complex syndromes with various manifestations de-
veloping from infancy to pre-school age, school age up
to adulthood. It is not surprising that the heredity trans-
missionpatternofatopicdiseasesdoesnotgoalongwith
Mendel’s genetics. Rather, it has to be assumed that
some genes make individuals susceptible to developing
asthma or other atopic diseases (polygene hereditary)
and/orthatdifferentcombinationsofgenemutationsare
present in patients with atopic diseases [37].
2.6.2 Environmental factors
2.6.2.1 Type and dimension of allergen exposure
It is well proven that the development of respective
sensitizationswillaugmentwithincreasingconcentrations
of indoor allergens in childhood especially in case of
genetically disposed individuals. This was illustrated
convincinglyinseveraltrialsforsensitizationstomiteand
catepithelia.Allergenconcentrationof2µg/gdustofDer
p 1, major allergen of house-dust mite, and respectively
8 µg/g dust of Fel d 1, major allergen of cat epithelia,
have been suggested as minimal doses to increase the
risk of sensitization. In case of bronchial asthma signifi-
cant elevated risks for developing asthma symptoms are
supposed to exist when a proband is exposed to more
than 10 µg/g dust of Der p 1 during infancy [37].
2.6.2.2 Nutrition
Prospective trials showed that hypoallergenic baby milk
cancauseatemporaryprotectiveeffectontheincidence
of atopic dermatitis, food allergy and infant obstructive
bronchitis.
Children with genetic disposition (at least one parent
sufferingfromallergy)developedatopicdiscomfortsmore
rarely during the first one to two years of their life if they
were breast feed or were fed hypoallergenic food (hydro-
sylates).
Other diet factors can be important in developing atopic
diseases as well. A lately published Australian trial
demonstrated that children with high consumption of
fresh oily fish had decreasedprevalences of asthma and
bronchial hyper reactivity [37].
2.6.2.3 Social factors and infant infections
Ithasbeenknownforalongtimethatallergiesrepresent
adiseaseofwealthypeople.Atpresent,highsocialstatus
influences the development of atopic diseases such as
allergic rhinitis. Furthermore, several trials displayed a
highlyinversecorrelationbetweenthenumberofbrothers
and sisters of a subject and the prevalence of hay fever
and atopic sensitization. In various trials this coherence
was documented consistently for children, adolescents
and adults in many countries. Thus bronchial asthma is
not associated in the same manner as hay fever and
atopy [37].
This means that single children have a significantly
higher risk to develop allergic sensitizations or hay fever
thanindividualsfromfamilieswithmanychildren.Intrials
with a big number of cases, it has been demonstrated
that older brothers and sisters have a higher protective
effectthanyoungerbrothersandsisters.Itwassupposed
that increased infantile exposure to viral and bacterial
infections of the upper respiratory tract could prevent
manifestation of atopic diseases [38].
This assumption is interesting regarding the different
prevalence of atopic diseases in Eastern and Western
European countries because the majority of children in
the former DDR (low sensitization rate) went to nursery
school after their first birthday. It was recently reported
that very early access to nursery school before consider-
ablyreducestheriskofallergicsensitization.Furthermore,
a noticeable inverse coherence was demonstrated in
Lithuania and Estonia between the number of persons
living in one household and atopic sensitizations: the
more individuals living in the same space, the fewer
people got allergies [39].
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countries. Recently, an US-american research team
showed that infantile non-obstructive infections of the
lowerrespiratorytract(especiallypneumoniaandtracheo-
bronchitis) are associated with a significant decrease of
IgE-level in serum and positive skin-prick-test rate later
inlifeofthosechildren.Furthermore,itwasdemonstrated
by an Italian research group that the detection of serum-
antibodies against hepatitis A was associated inversely
with the manifestation of asthma and atopy in early
adulthood [37].
Immunological trials dealing with the IgE-regulation ex-
plain the biological plausibility of the hypothesis that in-
fantile infections may prevent the development of atopic
sensitizations and manifestations of allergic diseases.
Simplified it can be assumedthat two T-helper-cell-popu-
lations exist that are needed to activate anti-body produ-
cing B-cells. TH2-cells enhance IgE-production by in-
creased release of certain cytokines like interleukin 4.
BycontrastTH1-cellsandtheircytokines(especiallyinter-
feron-y) inhibit the function of TH2-cells. The cytokine
interferon-y is also produced during the course of viral
infections.Ithasalsobeendemonstratedthatinterferon-
y is a strong inhibitor of many TH2-cell-functions and
consequently inhibits the IgE-synthesis
2.6.2.4 Environmental pollution
Exposure to passive smoking
Passively inhaled smoke of tobacco contains various
gases and particles with over 4,000 different chemical
bonds. Tar particles, carbon monoxide, nitrogen and
volatile hydrocarbon represent the most important com-
ponents. Passive smoking is the main source of indoor
pollution.Theconcentrationofpollutantsdependsonthe
numberofsmokers,theintensityoftheirsmokinghabits,
thesizeoftheapartmentandtheventilationsystem[40].
The pollution burden can reach immense dimensions by
passive smoking since children in westernized countries
stay most of the daytime indoor. Most information about
thedimensionandsourcesofpassivesmokingisderived
fromquestionnaires.Sometrialshavemeasuredcotinine,
adegradationproductofnicotine,inurine,salivaorblood
as an objective parameter of pollution with tobacco
smoke. But many trialsshowed that questionnairescoin-
cide well with the objective measurements. Therefore it
can be assumed that parents correctly report the actual
consumptionofcigarettesinanonymousscientificsurveys
[40].
Individual and socioeconomic factors are important
drivers which determine the individual sensitivity to
passive smoking. It can be assumed that adults reacting
sensitivelytothenegativeeffectsoftobaccosmokewould
smokeless,orwouldstopsmokingcompletely.Incontrast
children can not choose and can not influence their par-
ents smoking behaviour. Therefore it must be supposed
that a considerable portion of very sensitive children are
exposed to various pollutants of smoke.
Theconsequencesofactive-andpassive-smoking-expos-
ure have been explored in several trials. For infancy it
wasdemonstratedconvincinglythatpassivesmokingwill
significantly raise the risks for developing infections of
the lower respiratory tractlike bronchitisand pneumonia
(especially for babies and infants). Usually, the effects
are higher if the mother smokes in comparison to the
father. This is due to the fact that the child may be ex-
posed more frequently through close contact to the
mother or because pollutants affect a fetus.
The implications of maternal smoking during pregnancy
have been investigated in 80 babies shortly after child-
birth (on average 4.2 weeks later). Lung function tests
were used among others. The mothers smoking habits
havebeendocumentedviaquestionnairesandviaobject-
iveparameters(continine-concentrationinurine).Children
of smoking mothers displayed significantly lower forced
expiratory flows compared to healthy children.
Thelungfunctionmeasurementswereperformedshortly
after childbirth and were adjusted according to multi-
variant statistical models for short-time passive smoke
exposure of children. So, it can be assumed that the loss
of lung function test represents the implication of smoke
exposure in uterus. Those damaging effects are proven
until the age of 18 months. However, many factors point
out that the damaging effects will last longer.
2.6.2.5 Air pollutants
Sulphur dioxide and airborne particles
It does not seem to be reasonable that high concentra-
tions of SO2 and airborne particles can cause the devel-
opment of allergic diseases. The prevalence of asthma,
bronchial hyperreactivity, allergic rhinitis and atopic
sensitization has been significantly lower in regions with
high concentrations of SO2 and airborne particles like
EasternGermanyandPolandthaninlesspollutedregions
in Western Germany or Sweden [40], [41].
Traffic exposure
Until now, insufficient knowlegde is available about the
noxious effects of exposure to traffic. It was noticed that
theprevalenceofnon-specificrespiratorysymptomsand
a reduction of lung function can occur in children and
adults living in regions with high traffic volume [41].
In a Dutch trial, trucks caused higher effects than cars.
However, at the moment, it is unknown to what extent
this effect is attributed to soot or diesel exposure or to
increased airborne particle exposure. So far it could not
be confirmed that there are explicit effects on the preva-
lence of allergic rhinitis or atopic sensitization [42].
Ozone
Healthy and asthmatic subjects have been investigated
regardingeffectsofozoneonlungfunctionorrespiratory
discomfort mainly in climate trials. The extension of spir-
ometric alterations and of symptoms like coughing,
shortnessofbreathorinspiration-associatedpainvaried
a lot between probands concerning a certain degree of
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in some individuals’ reflecting possibly the reactivity to
ozoneofaparticularproband[42].Itwasshownbymany
investigatorsthatprobandsadaptrapidlytoacontinuous
exposure. Increase of bronchial reactivity to histamine
andmethacholinewasobservedinmanyhealthysubjects
after having been exposed to ozone. Therefore few indi-
cations point out that ozone might be a causal factor in
the development of allergic diseases [42].
3 Diagnostic methods for early
diagnosis of allergies
Diagnosis of allergic diseases is based on the typical
medicalhistorywithallergicsymptomsandontheresults
of diagnostic tests that target cell-bound IgE’s in in-vivo-
and in-vitro tests. These diagnostic tests consist of skin
tests,nasal-,conjunctival-andbronchial-provocationtests
and the detection of IgE in serum. Furthermore, early
diagnosis is focused normally on diagnosis in children,
for which reason specific aspects of clinical investigation
willbepresentedforpatientsinchildhoodinthefollowing
part.
3.1 Allergy diagnostics in childhood
Often first indicators for allergies can be found by ques-
tioning parents about eczema, chronic occurring gastro-
intestinal discomfort and frequent bronchial disorders in
the first month of life. At the age of about five years, ac-
complishingallergytestsandtheirclinicalbenefitbecome
asimportantasinadultallergicpatients.Theproceeding
is vaguer in younger children: overall, younger children
are tested more rarely by reason of faulty interpretation.
Allergytestingasearlydiagnosisbecomesmoreimportant
in this period of life due to the described conclusions of
immunological processes of sensitization especially in
the first month and early years of life. The relevance of
allergytestsisclarifiedinaprospectivetrialwithchildren
upto2yearsofagebyDelacourtetal.[43].Thisresearch
group demonstrated that those children, who developed
infantile bronchial asthma in all cases 18 months later,
suffered from an obstructive disease and had a positive
result in a prick-test against the house-dust mite D. pter-
onyssinus or to cat epithelia. The goal of optimal individ-
ual allergy diagnostics in childhood should be that chil-
dren with increased risk factors for developing allergic
diseases later on are identified as early as possible.
Identified candidates should receive a suitable therapy
withallergenavoidance,pharmacotherapyandcausative
allergen-specific immunotherapy.
3.2 Skin testing
3.2.1Anatomyandphysiology/immunologyof
skin (dermis)
The epidermis is not vascularised, and therefore the
corium contains a superficial vascular plexus extending
into the papillae between the two skin layers and a deep
vascular plexus from where plasma and inflammatory
cells can invade the skin. In addition, the corium holds
nerve fibres reaching up to the epithelial layer that can
contact mast cells and Langerhans-cells [44], [45].
Langerhans-cells belong to the dendrite cells and repre-
sent high potent APC [46], [47]. They are usually located
in the epidermis, and migrate
to local lymph nodes (SALT = Skin-associated lymphoid
tissue) after having been exposed to allergens [8]. In the
lymph-nodes they activate T-cells, which are normally
represented in a low number in the skin. Mast cells are
found in the corium and can release several different
mediators. Histamine is the most important mediator in
case of skin tests for type-1-allergies [48], [49]. It pro-
vokes vasodilatation (erythema) and plasma extravasa-
tions (oedema/wheel) within a few minutes.
3.2.2 Types of skin tests
Correspondingtothedifferentallergytypes,differentskin
tests are applied. Skin tests fit particularly well for diag-
nosis of type-I- and type-IV-allergies. Furthermore they
arewellstandardized.Type-IV-allergiesandcontactaller-
giesaretestedbytheepicutaneoustest(Patch-test)[50].
In this test, allergens (mainly small haptens penetrating
the epithelial barrier) wrapped in suitable vehicles are
applied to the top of the unmodified skin (mostly of the
back) Because the reaction is delayed, the skin is evalu-
ated after 48 hours and 72 hours, accompanied by a
generation of eczema. Skin tests for type-I-allergies are
thePrick-,Scratch-,andintracutaneoustest(asdescribed
below):
3.2.2.1 Skin tests for Type-I-Allergies
Pre-conditions and prearrangements
Prior to skin testing, the skin must react normally as a
pre-condition. Medications and other influences should
not increase or decrease skin reactivity. Allergy medica-
tion should generally be stopped (Table 3). Overshooting
reactionsasseenwithurticaria(factitia)canbeexcluded
e.g. by testing dermographism. Furthermore, the tested
area should not include alterations like eczema, and the
skin must be cleaned in order to prevent infections. The
use of non-specific therapeutic agents like ointments or
creams is prohibited in the testing area at the day of
testing. During the period before testing, other kinds of
skin irritations (physico-chemical influences) should be
avoided.
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Adequate treatment must be provided especially to chil-
drenbecausepatientscansufferfromunexpectedallergic
and other reactions (presence of a physician, first aid kit
and medication) [51]. Usually, children can be tested at
theageof5–6years(forcompliancereason).Inthiscase
thephysicianshouldknowhowtotreatemergenciesand
shouldbeequippedwithadequateemergencymaterials.
After testing, the person should be observed at least 30
minutes [52].
The selection of test allergens is adjusted to the individ-
ual’s specific set of allergy problems. It should include
the particular most frequent trigger allergens detected
in taking history.
Practical aspects of skin testing
Usually, testing of type-I-allergies is carried out at the
volar part of the forearms (given accessibility, reproduci-
bility, comparability). The distance between the testing
spots of two allergens must be far apart so that even two
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at least 2 cm; intracutaneous test: at least 5 cm). A
standardizedorderoftestallergensshouldbedetermined
(test protocol as below) and reference numbers of the
particular allergens should be written on the skin before
testing.
The (modified) Prick-Test [53] is completed by applying
abeadofallergensolutionontopoftheskinandpricking
into the skin with a needle (or lancet) in the area of the
bead [54], [55]. In this way parts of the allergen solution
areinsertedthroughtheepidermalbarrierintothecorium
by the lancet. Here the reactive mast cells are located.
When using Prick-(by-) Prick-tests [56] the lancet is
pricked into the allergen source (e.g. food) first, followed
by a direct skin puncture. Non-specific toxic or infectious
allergensourcesshouldbeavoidedforthelatterprinciple.
A negative control (solution substance) and a positive
control(dilutedhistamine)shouldalwaysbepartofPrick
testinginordertoseealterationsfromnormalskinreactiv-
ity. Between the “pricking” of the various test solutions,
the pricking-lancet must be cleaned thoroughly (e.g. by
wiping it with a sterile swab). The Prick-test is the recom-
mended method for skin testing [57], especially if suffi-
ciently standardised allergen extracts are available.
With the Scratch-test [57], the tested area of skin must
first be degreased and superficial horny lamellas must
beremovedby“tape-stripping”.“Tape-stripping”involves
placing adhesive strips on the skin and then removing
them.Inordertoincreasesensitivityscratchlinescanbe
createdby“Prick-lancets”inthetestingareaadditionally.
This decreases the specificity of the test enormously.
Afterwards the allergenic substance is wiped over the
prepared area and can remain on the skin. In this case,
non-specific toxic or infectious allergen sources should
be avoided as allergen sources as well. As a basic prin-
ciple, Prick-tests should be performed with standardized
allergen extracts whereas Scratch-tests should be used
only if required extracts are not available or their quality
is insufficient. Therefore, the Prick-(by-) Prick-test often
represents the better choice.
The most sensitive type of skin testing is the intracu-
taneoustest(ICT)(1,000timesmoresensitivethanPrick-
tests) [58], [59]. Thus they should not be performed un-
less Prick-testing is negative. Dangers to patients should
be avoided by all means. If less potent allergen prepar-
ations are used, ICTs often represent the best choice of
diagnosis. The applied testing solutions are diluted 100
times as high as those used in Prick-tests and have to be
diluted further if possible. Using a tuberculinum syringe
with a needle size of 26 G or 27 G 30–50 µl, the diluted
testing solution is injected strictly intracutaneously (in
ordertoavoidinjectionsintothedermalvascularplexus).
Injections of air interfere with adequate metering. A
negative control and a positive control should also be
carried along with this test. A new syringe and cannula
must be used for every injection.
Metering of skin tests
Themeter-readingofreactionsfromskinteststakesplace
after 15–20 minutes [60]. In this interval, allergic type-I-
reactions occur normally. It is recommended to observe
the test reactions intermittently during this time period
too. Late recations can develop hours or days later, or
reactionscanpersist(latephasereactionsamongothers).
These reactions can be allergologically relevant but nor-
mally they rarely appear at testing spots where an imme-
diate reaction was not noticed in type-I reactions. For the
metering [57], [61] the size of histamine reaction can be
used in relative grades 0-III or it can be measured using
absolute criteria (Table 4). Testing results should be
documented in written form or in preprinted test proto-
cols.
Table 4: Graduation of Prick-testing (intracutaneous testing)
3.2.3 Evaluation of testing results
Youngchildren,oldpatientsorcertainmedicalconditions
(e.g. poly-neuropathies, cancer-or dialysis- patients) gen-
erallyhavereducedskinreactivity[62].Usually,specificity
ofPrick-testsisup-ratedincomparisontointracutaneous
tests which are more sensitive [59], [63]. Normally,
positiveskintestscorrelatewellwithpositivein-vitro-tests
ofdeterminationofallergenspecificIgE-levelifthequality
of allergens is good and tests are performed correctly
[64].
In case of negative skin tests to a certain allergen a type-
I-allergycannotbeexcludeddefinitelyiftheskinreactivity
is decreased (often low or no histamine related reaction)
or the quality of the allergen extract is insufficient. (It
mightbethatallrelevantsingleallergensarenotincluded
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pired, etc.) The evidence of non-standardized tests (e.g.
Scratch-tests)hastobelimitedevenfurther.Furthermore
it is problematic that the skin is tested representatively
for the mucosa of the upper respiratory tract in allergies
of the upper air passages. When performing skin tests,
onlytheexistenceofsystemicsensitizationcanbeevalu-
ated but the clinical relevance (actuality) cannot. The
medicalhistoryorfurthertests,especiallynasalprovoca-
tiontestscanhelp.Discrepanciesbetweenskintestsand
medical history should be revaluated by taking a second
medical history.
Certainly, a positive skin test does not prove that a clinic-
allyrelevantsensitizationexists[65],[66].Ifnon-specific
reactions are excluded – what might be difficult in non-
standardised tests (like Scratch-tests) – positive results
only prove that allergen specific IgE is present on dermal
mast cells, which is functionally active and could lead to
mast cell de-granulation. This displays an important dif-
ference to the method of detection of allergen specific
IgE-levelinserumprovingtheexplicitpresenceofdistinct
immunoglobulin classes but neglecting the functionality
ofIgE-molecules.Inaddition,allergenspecificIgEpersists
on mast cells longer than in serum where IgEs show a
half-life of a few days. Therefore IgE can only be detected
in serum if it is produced during this certain period [67].
These considerations and maybe the different amount
of single allergens of allergen extracts for skin tests re-
spectively for in-vitro-testing can cause alterations
betweenbothkindoftestseventhoughthetestperform-
ance is correct.
Intwoconstellationsmedicalhistoryandskintestingcan
predicate confidently the diagnosis of type-I-allergies: as
in the case of seasonal allergens (pollen), symptoms
correlate with pollen flying times; in the case of good ac-
cordanceofsymptomsandallergenexposurelikeanimal
contactallergies(appearanceofsymptomsaftercontact
to the animal). Even though before starting therapeutic
steps(e.g.initializingofallergenspecificimmunotherapy,
extensive mite decontamination etc.) the relevance of
allergens should be supported by additional provocation
tests. Beside that the significance of other causes of the
respective symptoms should be excluded by other med-
ical investigations. This applies especially to perennial
allergens or allergens whose exposure happens in a hid-
den way (e.g. mites, mould funguses). The assessment
ofpossibletype-I-allergiesgetsspecificallydifficultinthe
caseofmedicaldrugs(metabolites,totalantigenproduc-
tion, few commercially available standardised test solu-
tions), food allergies (industrial processing, digestion,
arguable quality and stability of allergen extracts) and
mould funguses (incomplete knowledge about its aller-
gens, arguable quality of allergen extracts). In those
events, skin test results must be interpreted carefully
[68], [69].
3.3 In-vitro-methods for early diagnosis
of allergies
3.3.1 Measurement of total IgE
Serumcontainsaconsiderablylowconcentrationofanti-
bodies belonging to immunoglobulin class E (IgE) com-
paredtootherclassesofimmunoglobulins.IgEsareable
to provoke a specific reaction of the immune system by
linkingtoselective,high-orlow-affinitivecellularreceptors
[70] (Figure 3). They are structurally distinguished from
IgG-antibodies by additional CH-regions at the constant
region of the heavy chain. IgE-antibodies are particularly
important for type-I-allergies and therefore can be used
for early diagnosis of allergies.
Reference values of total-IgE for infancy have been
defined in the context of multi-centre trial [71] (Table 5).
Table 5: Reference values for total-IgE
According to the applied method and epidemiological
data basis normal values turned out to be a little higher
orlower[72].Themaximaldiffusionofthenormalvalues
was measured in the age of 6 years to 14 years [73].
3.3.1.1 Evaluation
Elevatedtotal-IgEinthecontextofallergydiagnosis: The
highest IgE-level could be detected in case of atopic
dermatitis. Concentrations of more than 10,000 U/ml
could be reached. In case of extremely high level of total-
IgE (>20,000 U/ml) the differential diagnosis of cellular
immune deficiency has to be excluded [74]. High total
IgEcombinedwithelevatedcountofeosinophilesshould
hint to a parasiticdisease[75]. Additionally, the elevated
total IgE-level can be found during the period of allergen
exposure. Generally, detection of total IgE in order to
screen for atopic diseases is less applicable than detec-
tion of specific IgE against common environmental aller-
gens. An elevated total IgE-level does not prove the
manifestation of atopic diseases; on the contrary, a nor-
mal total IgE-level does not exclude atopic diseases [76].
Atopic diagnosis in umbilical cord blood: Measurement
oftotalIgEinumbilicalcordbloodwassuggestedinorder
to diagnose early risks for newborn. Such a value can be
evaluated only if contamination of the cord blood by ma-
ternal blood was ruled out. Elevation of cord blood IgE
>0.9 U/ml is considered as a predictive parameter for
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of the IgE-reaction with different diagnostic principles and allergologic tests
the risk of atopy [77]. However values <0.9 U/ml can not
excludedevelopingofatopicdiseases.Thereforeumbilical
cord blood IgE-screening can not be recommended. This
method should be subjected to population with risk
factors like positive family history of atopy.
Immunodeficiency:Ahugenumberofcongenitalimmune
defects, especially of the cellular system can be accom-
panied by elevation of total IgE [78]. In the context of
immunodeficiencydiagnosticsmeasuringoftotalIgE-level
belong to the screening procedures of the humoral im-
munesystemtogetherwithallremainingimmunoglobulin
groups and subgroups.
3.3.2 Measurement of specific IgE (sIgE)
sIgE represents the fraction of total IgE-antibodies in
serum whose specificity to certain allergens can be de-
termined by in-vitro-tests. Detection of certain sIgEs
demonstrates a specific sensitization against corres-
ponding allergens (Figure 3). Afterwards it has to be
controlled whether the sensitization is clinically relevant.
Therefore sIgE represents only one parameter in the
classicalallerogologicaldiagnostic-conceptwhich is also
applicableforearlydiagnosisofallergies:medicalhistory
– skin testing – laboratory tests – provocation tests. In
case of the measurement of sIgEs the quality (pattern of
epitope, degree of purity) of the used allergens is import-
ant.
3.3.2.1 Indications of sIgE-measurement
DetectionofsIgEinserumandskintestingareconsidered
to be equivalent in allergy-diagnostics. In case of sIgE-
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distinguishedbetweenprimaryandsecondaryindications.
Primary indications for sIgE-analysis (before other diag-
nostic methods like skin tests):
• conditions, in which skin-tests are difficult to perform:
babies or infants •
skin alterations of the testing area •
Urticaria factitia •
Other contra-indications to skin-tests or other diag-
nostic methods (intake of antihistamines etc.),
•
Testing of allergens that are not available for skin
testing
•
• Danger for patients:
Anaphylactic shock or anaphylactic reaction in the
past
•
Suspected high grade sensitization (insect venom
allergy,medicaldrugallergy,especiallybeta-lactam-
antibiotics)
•
intake ofinterferingmedicationlike beta-blockeror
ACE-inhibitor
•
Secondary indications for sIgE-analysis (after other diag-
nostic methods):
in case of discrepancy between the results of skin
test an medical history
•
specialselectedclinicalsituationswhereadditional
estimation of the grade of sensitization is needed
•
– also, as additional preparation for provocation or
specific immunotherapy
3.3.3 Methods of determination of sIgE
3.3.3.1 Routine methods of determination
There exist several methods to determine sIgE being
basedonsimilarprinciples:specificallergenextractsand
partly available recombinant allergens are connected to
a solid phase or they are applied as fluid allergens to
which specific immunoglobulins will link after incubation
[79]. If solid phases are used, their surfaces as well as a
sufficient amount and quality of allergens should assure
that ideally all sIgEs can be bound. After removing un-
linked immunoglobulins, radioactive Anti-IgE-antibodies
markedwithfluorescenceorenzyme-linkedAnti-IgE-anti-
bodies are added. The linked Anti-IgE-antibodies are de-
termined either by direct determination of radioactivity
and fluorescence intensity or after adding a substance
by measuring the enzymatic induced color reaction. In
using a calibration curve related to know sIgE-amounts
the process can be quantified. Therefore, artificially
defined units or the calibration curve of total-IgE-values
definedbytheWHO(heterologousinterpolation)areused.
Hence, a real quantification of sIgEs is not possible so
far. Apart from the used allergens, the testing systems
differ from each other in regard to the solid phase for
linking allergen and the necessary reagents as well as
the following detection system (Table 6).
3.3.4 Interpretation of specific IgE-values
Screening-TestsforsIgE-antibodies: Abunchofscreening
tests for determination of sIgE against mixtures of food
and inhalation allergens are available. They are offered
especially for early diagnosis.
Onedifficultyofscreeningtestsisinsufficientevaluation.
A positive screening test only shows that a sensitization
exists against one or multiple allergens. In using semi-
quantitativetestsitcanbeassumedthatnegativeresults
cannot exclude sensitizations. Generally, screening is a
reasonable method if rationalization of the diagnostic
methodisreached.Nevertheless,thescreeningcharacter
of those methods should be obvious.
Table 7: Testing method for detection of allergen- and
antigen-specific IgG
3.3.5 Allergenspecific IgG/IgG4
OnthecontrarytoallergenspecificIgEtheserum-concen-
trationofallergenspecificIgG-antibodiesis100-to1,000
times higher. Thus, less sensitive methods of detection
can be used. There are several methods to determine
immunoglobulins qualitatively and quantitatively (Table
7). Some companies recommend determination of IgG
as a diagnostic method (especially of food allergens) on
andoff.ThoughallergenspecificantibodiesofisotypeM,
G, A can be found in sera of healthy persons as frequent
asinseraofatopicindividuals[80].Productionofallergen
specificantibodiesofthistypeofimmunoglobulinbelongs
to the normal immune response to impurity exposure.
Here, clinical symptoms do not correlate with the allergic
type-I-reaction. Their function in the pathogenesis of
bronchial asthma respectively allergy are unidentified.
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Concerning their clinical relevance the importance of
thoseantibodiesistotallyinsecure[81].Therefore,detec-
tion of allergen specific IgG- and IgG4- antibodies as a
method of early diagnosis of allergic type-I-diseases has
to be lowered.
3.4 Test systems with mast cells,
basophileandeosinophilegranulocytes,
T-lymphocytes and their products
3.4.1Mediatorsofbasophilegranulocytesand
mast cells
Mastcellsandbasophilegranulocytesareequippedwith
high-affine IgE-receptors and have the ability to release
rapid inflammatory mediators and immune-regulatory
cytokines [82]. They play a decisive role in the allergic
type-I-reaction.Assaysdeterminingcell-specificmediators
of body fluids (e.g. mast cell- tryptase, histamine) can in-
dicate acute or currently occurred activations of those
inflammatory cells (e.g. after anaphylactic reactions).
Theycanhelptodetectallergicdiseasesearly,especially
if general reactions have occurred that cannot definitely
be allocated to allergic genesis.
Histamines and their metabolites can be determined in
body fluids by various sensitive and specific methods;
mainlyusingtheimmunoassaytechnique[83].Detection
inplasmaorurineisnotimportantfordiagnosisofallergic
diseases because of the rapid metabolism in organisms
and influence of several variables. In contrast to hista-
mine, the tryptase is degraded more slowly (serum-half-
life: 2 hours), and tryptase can help to detect events of
mastcellinvolvementretrospectively[84].Thisisimport-
ant in the context of early diagnosis of allergic diseases
because those markers can predict severe courses of
allergic reactions (anaphylaxis).
Indications for tryptase measurement:
• Questionable reactions with mast cell involvement
within the last 24 hours, e.g. IgE mediated reactions
by immediate type-I-allergens (insect venom, food al-
lergy among others), anaphylactic reactions (pharma-
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others),
• To find the cause/activator of a shock reactions
(<24 h)
• Questionable mastocytosis (e.g. elevated basal tryp-
tase-level as a hint to mastocytosis [85])
• Differentvariablesinfluencetheresultandcomplicate
interpretation:
Degree of severity of reaction •
Time course of events and moment of blood with-
drawal [86],
•
Individual aberration of mast cell activation and
tryptase-level
•
No availability of common valid standard values •
While high tryptase-level (>12.5 µg/l) along with low
basallevelcanargueforinvolvementofmastcells,values
in normal range do not mean a lot (possibly false nega-
tive). Tryptase-level measurement does not show advan-
tages over clinical evaluation for monitoring of moderate
allergic events (e.g. beginning IgE-mediated food allergy
reaction after oral provocation) by reason of insufficient
sensitivity [87].
3.4.2Mediatorsfromeosinophilegranulocytes
Esosinophilegranulocytesparticipateinthepatho-genesis
of allergic diseases decisively. Augmented numbers of
eosinophilescanbedetectedinthemucousmembranes
of the upper and lower respiratory tract of allergic pa-
tients, as well as in the skin of patients with atopic
dermatitis. The measurable mediators in serum reflect
the numberof eosinophilesandthe degreeof activation.
Therefore,theydemonstratethedegreeandactualstatus
of inflammatory reaction.
Several investigations are based on the detection of
“Eosinophil Cationic Protein” (ECP) [88] depending on
pre-analytics in a high degree: the release of ECP from
eosinophile granulocytes is induced depending on the
degree of activation during clotting of the whole blood
(pre-analytical preparation: 1 h at room temperature,
meaning 18–22°C). ECP can be measured in other bio-
logical fluids (e.g. serum, “lavage”-fluid) by means of im-
munoassays(serumreferencerangeforadults:<15µg/l).
ECP- measurement is not suited for individual prediction
because of its tremendous inter-individual dispersion.
Considering this fact, elevated ECP-level cannot help in
diagnosticsnorinanexplicitallocationtoaspecificillness
[89]. In selected cases, ECP-measurement can be used
for follow-up of severeatopic diseases[90] providedthat
other follow-up parameters are not available.
3.4.3 Cellular allergen stimulation tests
Cellularin-vitro-tests forspecificallergydiagnosticsserve
mainly as indirect detection methods of sensitization of
basophile granulocytes (by reason of easy availability
compared to mast cells). Some cellular in-vitro-test sys-
tems for type-I-allergy diagnostics use the principle of
detectingmediatorsorcellularantigensappearingonthe
surface of cells after successful activation. For this im-
munologic reaction blood leucocytes are concentrated
by dextran-sedimentation and are incubated with aller-
gens or other trigger factors. Surface marker (CD63) ex-
pressed after allergen stimulation or released mediators
of basophile granulocytes (e.g. histamine, sulfido-leuko-
trienes) serve as indirect parameter for cellular bound
sIgE (Figure 3). The cellular IgE-independent reactivity
preparednessofinvolvedleucocytesis reflectedby other
activators (bacterialpeptidefMLP, complementcompon-
entC5a)thatcauseasuccessfulactivationandmediator
release.
Inimitatingmajorpartsoftheimmunologicreactionchain
of allergic reactions in in-vitro-/ex-vivo-experiments, it
wasexpectedforalongtimethatherebyallergicreactions
could be diagnosed at an early stage. In this way, those
testing methods could especially have been applied for
earlydiagnosis.Bell-shapeddose-response-curves(Figure
4)resultinusingtestsystemswithrisingallergenconcen-
trations.Theslopeofthecurvecorrelateswiththecellular
sensitization,butdoesnothaveanyrelationshipwiththe
maximum of those curves. (Cellular reactivity represents
a diagnostically irrelevant factor for signal transmission
normally[91].) Allergenspecific mediator-dose-response
curves are extremely variable intra and inter-individually.
Thereforearelease-testisinsufficienttodetectsensitiza-
tion if only one allergen concentration is tested. It must
beaddedthatbasophilesofabout5–15%celldonorsdo
not have the ability to release mediators after IgE-medi-
ated stimulation even though cellular IgEs are present
(non-responder). So, significance of cellular tests is less
significant than direct IgE-measurement. They are meth-
odically laborious; they do not apply for transports of
probes; they are expensive and hard to conduct and in-
terpret.Thereforetheyarenotasrelevantforallergologic-
alroutinediagnosticsandespeciallynot forearlydiagno-
sis of allergic diseases. Adequate indications might be
samples with low total-IgE and ineffective detection of
sIgEeventhoughasensitizationwassuspectedorincase
of rare allergens. Due to the technical requirements and
thecomplexinterpretationtheyshouldbeperformedonly
by physicians that do have extensive experience with
specialized cellular allergy tests.
3.4.4 Activation and histamine-release of
basophile granulocytes
In basophile-de-granulation-tests cells are stained and
counted before and after stimulation with allergens. At
the moment, this method is not important by reason of
an unacceptable dispersion. The histamine-release-test
with allergens measures the released histamine of
basophilesfluorimetricallyorbymeansofimmunoassays.
As a positive control, cells are incubated with anti-IgE-
antibodies [92]. The released histamine is alluded to in
percentages to the total histamine of cells determined
by lyses in a parallel preparation (Figure 4). This test is
performed only by a few centres and is preserved mainly
for special diagnostic or scientific questions because no
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advantages exist for this test in routine diagnostics of
IgE-mediated allergies compared to the method of direct
IgE-measurement. Flow cytometry represents another
method to investigate basophile-activation. Those
methods use the new expression of CD63 at the surface
of basophile granulocytes after successful stimulation
via allergens. This kind of testing can be an alternative
to the in-vitro-histamine-release-test in case of existent
technical equipment and sufficient experience.
3.4.5 Measurement of other effectors-cell-
mediators (Leucotrien-release-test)
Though other preformed or new synthesised mediators
of effector-cells can be measured too especially sulfido-
leukotrienes (SLT) have been used beside histamine for
allergy diagnostic so far. In using type-I-allergens the
leukotriene-release-test(e.g.CellularAntigenStimulation
Test, CAST [93]) permits an indirect detection of cell-
bound IgE as well (Figure 3). After mixed leucocytes have
been pre-activated with interleukin-3 and have been
stimulated new-synthesised SLT can be measured
quantitativelyinimmunoassaysonELISA-basis.Basically,
the same conditions count as for the histamine-release-
test [94]. However the concentrationof mediators will be
higher due to the pre-treatment with interleukin-3 espe-
cially in donors with fewer release [95]. As a positive
controlforallergeninducedreleaseservesamonoclonal
anti-Fc-IgE-receptor-antibody.TheSLT-releaseisincreased
in adding further stimuli like C5a, fMLP or PAF. Whether
the test can deliver diagnostic information in case of in-
tolerance-reactionsbythismodification[96]Whetherthe
test can possibly deliver diagnostic information in case
of intolerance reactions (e.g. acetylsalicylate acid as
model for a non-IgE-mediated intolerance) by this modi-
fication [96] has to be investigated in further controlled
trials.
Selected allergological diagnostic problems can indicate
the use of leukotriene-release-test in particular cases
[97], [98], as long as other methods (skin test, sIgE-
measurement) have already been performed (Table 8).
The leukotriene-release-test cannot be recommended at
the moment in order to identify pseudo-allergens.
In order to evaluate the test results negative controls
(stimulation with puffer and interleukin-3) and positive
controls (stimulation with anti-Fcε-RI, calcium-ionophor)
are supplied for IgE-mediated release of the mediator.
Beside that other controls (C5a, fMLP, PAF) are attached
in order to investigate other stimulation mechanisms. A
positive reaction to an allergen (meaning the indirect
proof of sensitization) is only indicative for a clinically
relevant allergy in combination with a corresponding
medical history.
Theleukotriene-release-testrepresentsacomplexcellular
test-system which is especially important in continuative
in-vitrodiagnosticandnotintheroutineallergydiagnostic.
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How far the test can be applied in pseudo-allergic reac-
tions or for therapy-monitoring has to be tested in add-
itional controlled trials. In case of explicit indications,
controlledaccomplishmentandcriticalinterpretationthe
leukotriene-release-testmightbepartofaspecializedin-
vitro allergy diagnostic potentially.
3.4.6Determinationofbasophile-activationby
means of flow cytometry
The activation of basophile granulocytes can be also be
quantified by cytrometry detection of the surface marker
CD63[99]afterallergenstimulation.Singleinvestigations
withpollen-[100],insectvenom-[101]andfoodallergens
[102] proved efficiency of CD63-detection for diagnostic
questionsinsmallpatientcollectives.How farbasophile-
activation-tests by means of flow cytometry represent a
potential method for early diagnosis of allergies has to
be approved by further controlled trials.
3.4.7 Lymphocyte-stimulation-tests (LST)
The application of in-vitro-tests is limited in diagnostics
of cellular mediated allergic reactions so far. At the mo-
ment, the lymphocyte-transformation-test is the most
commontest.IntheLST,lymphocyte-culturesareexposed
to the suspected allergen in attendance of antigen-
presentingcells.Theinsertionoftritium-markedthymidin
(3H-thymidin) is mainly used to estimate the lymphocyte-
transformation.TheLSTprovesaspecificT-cell-response
of mononuclear cells isolated from blood against the
antigen/allergen. One problem with the LST is that it
cannotbedistinguishedbetweenaphysiologicalresponse
to the antigen and an allergic T-cell-response.
Skin tests and in-vitro-tests do not show useful results
forskinlesionslikeexanthemaafterintakeofmedication.
Therefore, drug related exanthema display the most fre-
quentindicationsforLSTinordertoclosethe“diagnostic
gap”. Additionally, other reactions are linked to medical
drugs like allergic vasculitis, aplastic anemia or hepatitis
in which LST was used a diagnostic tool [103], [104].
Extremely good results are achieved by the use of LST in
penicillin allergies. This led to further investigations of
mechanisms of cellular immune reactions against peni-
cillin[105],[106],[107].Alsointhecaseofcarbamazepin
and phenytoin, it was published that LST-results are
meaningful when considering an immunologic setting
[108]. There are some notifications of a small number of
cases about positive LST in further pharmceuticals like
nitrofurantoin, chinidin, nystatin, captopril, ibuprofen,
aminophenazonoderpropyphenazon[109].Nyfelderand
Pichler declared a diagnostic sensitivity of 74–78% and
aspecificityof85%inoneoftheirpublicationsindicating
thatthistestisnotworsethanotherallergologicaltesting
procedures [110]. There are also reports that positive
LSTofbloodlymphocytesinproteininducedallergieslike
food allergies [111], [112], [113] or aggravations of
atopicdermatitisarecausedbyinhalationallergens[114].
In order to clarify type-I-reactions and allergic contact
dermatitis,moresensitivetestingprocedures(skintests,
specific IgE) are usually available. How easily LST can be
interfered by certain substances can be demonstrated
using the example of endotoxins. They can be found fre-
quently in protein fractions and can cause false positive
results of milk-protein-measurements in control individ-
uals [112], [113]. Due to those findings, a detoxification
ofcommercialproteinfractionsorallergenextracts[115]
must be used before its use in LST.
Anothergroupofallergensareclassicalcontactallergens
likenickelsulphate,chromatesalsorisothiazoline[116],
[117], [118]. Furthermore, LST is a suitable test to prove
sensitizations against beryllium. Diagnosis of berylliosis
represents the best established indication for LST [119].
Inhigherconcentrations,somecontactallergenscanact
as mitogenes (obligate stimuli) postulating an individual
balanced titration. Whether the partly bad specificity of
LSTcanoriginatefromnon-optimalconditionsinanalysis
ofmetalcombound[120]cannotbesaidatthemoment.
Good correlations can be achieved between LST and
epicutaneous testing for nickel sulphate [117], [118].
Consistently, false negative reactions of LST have been
observed which limit the application and acceptance of
this test in routine diagnosis [106], [121], [122]. There
are various reasons for negative results:
The observed reaction in patients is not caused by
immunological mechanisms.
•
It was mistimed, e.g. too early after treatment with
steroids, or the period has been to long between
allergen contact and taking the blood sample
•
Ametaboliteinsteadofthemedicationthatwasnot
tested in-vitro causes the allergic reaction [104],
[123].
•
The medical drug inhibits the insertion of thymidin
by its own pharmacological effect [121].
•
By adding enzymes to the test, sera 3H-thymidin is
degraded encymatically in a more extensive way
than in controls [124].
•
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low numbers of sensitized memory-cells in blood
that probably react in LST.
•
3.4.8 Variations and possibilities to develop
cellular in-vitro-test-systems
The explanatory power of LST has been improved in pre-
incubating antigens with liver microsomes containing
cytochrome-P450 especially in case of sensitizations
againstpyrazolonesandanticonvulsivesbecausemetab-
olites can be detected as well [104], [121], [123]. New
read-out-systems provide interesting perspectives for
advancement of cellular in-vitro-diagnostics of allergic
reactionslikethemeasurementofcytokines(MTT-assay)
ortheflowcytometrydisplayofdividingcellsafteradding
a stimulus [125]. Flow cytometry analysis of LST with
activation markers (meaning membrane molecules that
can be detected more or less after antigen-triggering)
seem to be less sensitive than the determination of
thymidin-insertion [126], [127]. Even though flow cyto-
metry promises to reach a higher specificity of LST in
separating lymphocyte-subpopulations by functional as-
sociatedmarker(e.g.measurementofallergen-triggered
CLA+-blood-lymphocytes in cutaneous inflammations
[128], [129] or of alpha4beta7+-lymphocytes in food al-
lergies [130]).
3.5 Therapeutic consequences from
early diagnosis of allergies
The early diagnosis of allergic diseases allows a specific
intervention while considering the following therapeutic
aspects:
Abatement/Removal of the patients symptoms •
Preventionofsecondarydamages/developmentof
persistent inflammatory processes in mucous
membranes of the respiratory tract
•
Reductionoftherisktodevelopabronchialasthma
and further allergy-associated diseases
•
Reduction of the risk to develop further sensitiza-
tions
•
The therapeutic efficiency of allergen specific immuno-
therapywithsubcutaneousinjections(SCIT)withallergens
and respectively chemically modified allergen extracts
(Allergoids) could be demonstrated in several trials (re-
views in [131], [132], [133]).
SCIT is also a cost-effective treatment in consideration
of economic factors like the reduction of the medication
usage,increaseofproductivityandrespectivelydecrease
of absences of work and diminished prevalence of new
sensitizations and allergic asthma [134], [135].
3.6PreventiveeffectsofSITwithregard
to the development of allergicbronchial
asthma
The data of the PAT-trial is important in order to evaluate
the early treatment by SIT. This European multi-centre
trial showed a significant decrease of the development
of a manifest bronchial asthma (Figure 5) [136].
They have treated 144 children with allergic rhinitis (AR)
eitherwithSCITormedicinallyforaperiodofthreeyears.
Interestingly, it was observed that children showed a
significantlydecreasedprevalenceofasthmahavingbeen
assigned to the SIT treated group after three years of
therapy. Furthermore, a preventative long-term effect
couldbeprovenregardingthepreventionofasthma.Even
seven years after finishing SCIT, children developed sig-
nificantly fewer allergic asthma than the control group
[137]. Considering these results, the immunotherapy is
the only known therapy that reduces the development of
bronchial asthma in patients with allergic rhinitis.
3.7 Prevention of additional allergic
sensitizations
Explicitevidenceexiststhattheprevalenceofnewallergic
sensitizations can be decreased by SCIT. A prospective
trialwaspublishedwith44childrensufferingfromhouse
dust mite allergy. They showed that the rate of new
sensitizations can be reduced significantly by a 3-year
SCIT[138].Theyalsodiscoveredsimilarpreventiveeffects
in a retrospective open-label-trial with 8,396 patients for
a observation period of seven years [139].
4 Summary and future prospects
Allergic diseases belong to the most frequent diseases
of humanity. Their prevalence is growing dramatically in
all industrialised countries.
Allergiesoftencauseatopicdermatitis,allergicrhinitisor
bronchialasthmainearlychildhood.Besidesconsiderably
restricting symptoms, allergies affect the life quality of
patients, their social life, and school and work productiv-
ity.
Allergic diseases are characterized by various comorbid-
ities which arise depending on the duration of illness.
Additionally,theaffectedtissuecanbedamaged.Further-
more, a chronic persistent inflammatory alteration of tis-
sue can occur which may be irreversible. During the
course of the disease, the number of allergens to which
the individual patient reacts can also increase. All these
issues combined can have tremendous consequences
on the direct, indirect and intangible costs of a health
system and overall economy. Diagnosis and treatment
ofallergicdiseasesasearlyaspossiblecanpreventsome
of the outcomes (secondary prevention).
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Klimek et al.: Early detection of allergic diseases in otorhinolaryngology...Figure 5: Allergen specific immunotherapy can avoid the development of allergic bronchial asthma in patients with allergic
rhinitis (according to [136])
It was demonstrated that early diagnosis of allergic dis-
eases makes specific immunotherapy more efficient. In
this way comorbidities can be avoided (e.g. bronchial
asthmainpatientswithallergicrhinitis)andtheexpansion
of sensitization can be limited.
In the future, improved diagnostic methods can further
enhance accurate detection.
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